Clinical Trials
12 trialsNCT03567889 2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3 Recruiting
NCT00118313 2020-03-27
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
Phase 1 Completed
NCT00006249 2015-02-10
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT00025181 2014-05-22
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
University of Southern California
Phase 1 Completed
NCT00031733 2014-05-22
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Phase 2 Completed
NCT00489944 2014-01-10
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00492505 2014-01-10
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01082198 2013-08-26
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00002455 2013-08-07
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00085579 2012-12-12
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00005052 2009-02-09
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
National Cancer Institute (NCI)
Phase 3 Unknown